Please login to the form below
AbCellera
This page shows the latest AbCellera news and features for those working in and with pharma, biotech and healthcare.
Eli Lilly/AbCellera’s COVID-19 variant-targeting antibody enters clinical trials
An antibody targeting variants of COVID-19, developed as part of a collaboration between Eli Lilly and Canadian biotech company AbCellera, has entered clinical trials. ... AbCellera added that LY-CoV1404 is ‘substantially more potent’ in viral
Latest news
-
Eli Lilly begins COVID-19 prevention trial in nursing homes
The mAb is being developed in collaboration with AbCellera, following a co-development agreement signed in March for COVID-19 treatments. ... LY-CoV555 is the result of this early screening, and is now the lead candidate from Lilly’s collaboration with
-
Lilly and AbCellera partner on antibody therapies for COVID-19
The collaboration will leverage AbCellera’s pandemic response platform and Lilly’s global capabilities for the rapid development and subsequent manufacturing and distribution of therapeutic antibodies. ... AbCellera's platform has delivered, with
More from news
Approximately 3 fully matching, plus 0 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- Roche’s Polivy recommended by NICE for lymphoma therapy
- Sanofi/Regeneron’s Dupixent approved by EC for eosinophilic oesophagitis
- ASH 2022: bad blood but big advances
- AbbVie’s Rinvoq approved by MHRA for Crohn's disease
- GSK’s Benlysta given orphan drug status by FDA for systemic sclerosis
- AstraZeneca’s Imfinzi plus chemotherapy approved by MHRA for biliary tract cancer
- ICR calls for improved biomarker cancer tests to help personalise treatment
- EIT Health marks World Cancer Day with €6m pledge for new healthcare delivery models
- World Cancer Day: encouraging men to put their health first
- World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
- Strategic behaviour
- Creabilis names Catherine Moukheibir as chairman of the board
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- MIT researchers develop AI model to detect future lung cancer risk
- World Health Organization releases latest set of COVID-19 guidelines
- Neurodiversity and healthcare communications – do we know enough and do we do enough?
PMHub
Wisepress
Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...
Latest intelligence
- World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
- Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
- Strategic behaviour
- Strong strategising depends on your colleagues’ behaviour...
- Pharmaceutical Marketing Strategies For The Digital Age
- In the digital age, a strong digital marketing strategy is crucial for businesses, especially in the highly competitive and complex pharmaceutical industry. There are key trends shaping pharmaceutical marketing, such...
